title: [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
authors.affiliation: Unidad de Gestión Clínica de Dermatología, Hospital Universitario Virgen Macarena, Sevilla, España. dmoreno@e-derma.org
authors.forename: D
authors.initials: D
authors.lastname: Moreno-Ramírez
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003880:Dermatology / Q000191:economics; D004334:Drug Administration Schedule; D016527:Drug Costs; D004363:Drug Utilization / Q000191:economics; D000068800:Etanercept; D006748:Hospital Departments / Q000191:economics; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000191:economics; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept